Preview
Unable to display preview. Download preview PDF.
Références
Biancone L et al. Hepatitis B and C virus infection in Crohn’s disease. Inflamm Bowel Dis 2001;7:287–94.
Loras C et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009;104:57–63.
Vivarelli M et al. Influence of steroids on HCV recurrence after liver transplantation. A prospective study. J Hepatol 2007;47:793–8.
Nissen MJ et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology 2005;44:1016–20.
Aslanidis S, Vassiliadis T, Pyrpasopoulou A et al. Inhibition of TN Falpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007;26:261–4.
Campbell S, Ghosh S. Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001;13:191–2.
Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004;51:580–4.
Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004;51:800–4.
Vauloup C et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 2006;17:290–3.
Peterson JR et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Rheum Dis 2003;62:1078–82
Zein NM. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C infection: a phase 2 randomized, double blind, placebo-controlled study. J Hepatol 2005;42:315–22.
Villa F et al. Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases. Eur J Gastroenterol Hepatol 2005;17:1243–5.
Salcedo-Mora X et al. Chronic hepatitis C and Crohn’s disease: nosoco-mial infection treatment with PEG-interferon plus ribavirin. Digestion 2006;73:210–4.
Tilg H et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003;52:1728–33.
Peyrin-Biroulet L etal. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Aliment Pharmacol Ther 2008;28: 984–93.
Melmed GY et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101:1834–40.
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507–39.
Cheng AL et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV carriers with lymphoma. Hepatology 2003;37:1320–8.
Esteve M et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004;53:1363–5.
Millonig G et al. Subfulminant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening? World J Gastroenterol 2006;12: 974–6.
Ojiro K et al. Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. J Gastroenterol 2008;43:397–401.
Madonia S et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007;13:508–9.
Yeo W et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299–307.
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 2009 Springer-Verlag France, Paris
About this chapter
Cite this chapter
Bronowicki, J.P. (2009). Prise en charge d’une MICI avec une hépatopathie chronique. In: Greff, M. (eds) Post’U FMC-HGE. Springer, Paris. https://doi.org/10.1007/978-2-287-99247-6_3
Download citation
DOI: https://doi.org/10.1007/978-2-287-99247-6_3
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-99246-9
Online ISBN: 978-2-287-99247-6
eBook Packages: MedicineMedicine (R0)